Predicting 10-year risk of type 2 diabetes in Chinese people with overweight or obesity treated with Tirzepatide: Post hoc analysis of SURMOUNT-CN trial

What Was Tested

This randomized controlled trial paper looks at Tirzepatide.

To assess the association of tirzepatide use with a 10-year predicted risk of type 2 diabetes (T2D) among Chinese participants with obesity or overweight from the SURMOUNT-CN trial.

A mixed model for repeated measures was used to compare mean predicted risk changes from baseline to weeks 24 and 52 between tirzepatide and placebo.

Who Took Part

PubMed indexes the participants as adults, middle-aged adults and older adults, both men and women.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

The participants were allocated by chance, so the Tirzepatide group and the comparison group should start out alike.

As a double-blind Tirzepatide study, the assignments were hidden from both participants and investigators until the end.

The comparison arm used a placebo, so changes seen with Tirzepatide could be set against what happens without it.

Subgroup analyses were conducted by baseline body weight mass index (BMI) status and baseline prediabetes status.

What Was Measured

Topics PubMed links to this paper include Diabetes Mellitus, Type 2, Overweight, Obesity, Tirzepatide, China, Risk Factors and Body Mass Index.

The authors tagged it with the keywords prediabetes, risk prediction and type 2 diabetes.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Tirzepatide.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2025 (Diabetes, obesity & metabolism), a journal based in England.

More context: the Tirzepatide compound page, all human trials.